The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Richard Eastell

Academic Unit of Bone Metabolism

University of Sheffield

Herries Road

Sheffield S5 7AU

United Kingdom

[email]@sheffield.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Academic Unit of Bone Metabolism, University of Sheffield, Herries Road, Sheffield S5 7AU, United Kingdom. 2005 - 2011
  • National Institute for Health Research Bone Biomedical Research Unit, University of Sheffield, Sheffield, United Kingdom. 2011
  • NIHR Bone Biomedical Research Unit, Centre for Biomedical Research, Northern General Hospital, Herries Road, UK. 2011
  • University of Sheffield, Sheffield, United Kingdom. 1998 - 2011
  • University of Sheffield Bone Metabolism Group, Metabolic Bone Centre, Sorby Wing, Northern General Hospital, UK. 2009 - 2010
  • Division of Clinical Sciences, Northern General Hospital, Sheffield, England S5 7AU. 2002 - 2009
  • Academic Unit of Bone Metabolism, Division of Clinical Sciences (North), School of Medicine and Biomedical Sciences, University of Sheffield, UK. 2005 - 2007
  • Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK. 2000 - 2006

References

  1. Effect of stopping risedronate after long-term treatment on bone turnover. Eastell, R., Hannon, R.A., Wenderoth, D., Rodriguez-Moreno, J., Sawicki, A. J. Clin. Endocrinol. Metab. (2011) [Pubmed]
  2. Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence. Eastell, R., Vrijens, B., Cahall, D.L., Ringe, J.D., Garnero, P., Watts, N.B. J. Bone Miner. Res. (2011) [Pubmed]
  3. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Eastell, R., Christiansen, C., Grauer, A., Kutilek, S., Libanati, C., McClung, M.R., Reid, I.R., Resch, H., Siris, E., Uebelhart, D., Wang, A., Weryha, G., Cummings, S.R. J. Bone Miner. Res. (2011) [Pubmed]
  4. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Eastell, R., Rogers, A., Ni, X., Krege, J.H. Osteoporos. Int (2011) [Pubmed]
  5. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Eastell, R., Adams, J., Clack, G., Howell, A., Cuzick, J., Mackey, J., Beckmann, M.W., Coleman, R.E. Ann. Oncol. (2011) [Pubmed]
  6. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. Eastell, R., Nagase, S., Ohyama, M., Small, M., Sawyer, J., Boonen, S., Spector, T., Kuwayama, T., Deacon, S. J. Bone Miner. Res. (2011) [Pubmed]
  7. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Eastell, R., Chen, P., Saag, K.G., Burshell, A.L., Wong, M., Warner, M.R., Krege, J.H. Bone (2010) [Pubmed]
  8. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Eastell, R., Lang, T., Boonen, S., Cummings, S., Delmas, P.D., Cauley, J.A., Horowitz, Z., Kerzberg, E., Bianchi, G., Kendler, D., Leung, P., Man, Z., Mesenbrink, P., Eriksen, E.F., Black, D.M. Osteoporos. Int (2010) [Pubmed]
  9. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Eastell, R., Arnold, A., Brandi, M.L., Brown, E.M., D'Amour, P., Hanley, D.A., Rao, D.S., Rubin, M.R., Goltzman, D., Silverberg, S.J., Marx, S.J., Peacock, M., Mosekilde, L., Bouillon, R., Lewiecki, E.M. J. Clin. Endocrinol. Metab. (2009) [Pubmed]
  10. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. Eastell, R., Black, D.M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K., Cummings, S.R., Delmas, P.D., Palermo, L., Mesenbrink, P., Cauley, J.A. J. Clin. Endocrinol. Metab. (2009) [Pubmed]
  11. Bone turnover markers: a key tool for understanding osteoporosis. Eastell, R., Ebeling, P.R. Osteoporos. Int (2009) [Pubmed]
  12. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. Eastell, R., Adams, J.E., Coleman, R.E., Howell, A., Hannon, R.A., Cuzick, J., Mackey, J.R., Beckmann, M.W., Clack, G. J. Clin. Oncol. (2008) [Pubmed]
  13. Biomarkers of bone health and osteoporosis risk. Eastell, R., Hannon, R.A. Proc. Nutr. Soc (2008) [Pubmed]
  14. Bone turnover markers: an appreciation of the contribution of Dr. P.D. Delmas. Eastell, R. Bone (2008) [Pubmed]
  15. Aromatase inhibitors and bone. Eastell, R. J. Steroid Biochem. Mol. Biol. (2007) [Pubmed]
  16. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Eastell, R., Krege, J.H., Chen, P., Glass, E.V., Reginster, J.Y. Curr. Med. Res. Opin (2006) [Pubmed]
  17. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Eastell, R., Hannon, R.A., Cuzick, J., Dowsett, M., Clack, G., Adams, J.E. J. Bone Miner. Res. (2006) [Pubmed]
  18. Does warfarin increase the risk of osteoporotic fracture?. Eastell, R. Nature Clinical Practice. Endocrinology & Metabolism (2006) [Pubmed]
  19. Role of oestrogen in the regulation of bone turnover at the menarche. Eastell, R. J. Endocrinol. (2005) [Pubmed]
  20. Long-term effects of aromatase inhibitors on bone. Eastell, R., Hannon, R. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  21. Management of bone health in postmenopausal women. Eastell, R. Horm. Res. (2005) [Pubmed]
  22. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Eastell, R., Barton, I., Hannon, R.A., Chines, A., Garnero, P., Delmas, P.D. J. Bone Miner. Res. (2003) [Pubmed]
  23. Management of osteoporosis due to ovarian failure. Eastell, R. Med. Pediatr. Oncol. (2003) [Pubmed]
  24. Diet and healthy bones. Eastell, R., Lambert, H. Calcif. Tissue Int. (2002) [Pubmed]
  25. Strategies for skeletal health in the elderly. Eastell, R., Lambert, H. Proc. Nutr. Soc (2002) [Pubmed]
  26. Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?. Eastell, R., Reid, D.M., Compston, J., Cooper, C., Fogelman, I., Francis, R.M., Hay, S.M., Hosking, D.J., Purdie, D.W., Ralston, S.H., Reeve, J., Russell, R.G., Stevenson, J.C. QJM (2001) [Pubmed]
  27. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Eastell, R., Devogelaer, J.P., Peel, N.F., Chines, A.A., Bax, D.E., Sacco-Gibson, N., Nagant de Deuxchaisnes, C., Russell, R.G. Osteoporos. Int (2000) [Pubmed]
  28. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. Eastell, R., Reid, D.M., Compston, J., Cooper, C., Fogelman, I., Francis, R.M., Hosking, D.J., Purdie, D.W., Ralston, S.H., Reeve, J., Russell, R.G., Stevenson, J.C., Torgerson, D.J. J. Intern. Med. (1998) [Pubmed]
 
WikiGenes - Universities